Clearside Biomedical Stock EBITDA
| CLSD Stock | USD 1.05 0.02 1.87% |
Clearside Biomedical fundamentals help investors to digest information that contributes to Clearside Biomedical's financial success or failures. It also enables traders to predict the movement of Clearside Stock. The fundamental analysis module provides a way to measure Clearside Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearside Biomedical stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -23.1 M | -24.2 M |
Clearside | EBITDA |
Clearside Biomedical Company EBITDA Analysis
Clearside Biomedical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Clearside Biomedical EBITDA | (23.06 M) |
Most of Clearside Biomedical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearside Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Clearside EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Clearside Biomedical is extremely important. It helps to project a fair market value of Clearside Stock properly, considering its historical fundamentals such as EBITDA. Since Clearside Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Clearside Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Clearside Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Clearside Ebitda
Ebitda |
|
According to the company disclosure, Clearside Biomedical reported earnings before interest,tax, depreciation and amortization of (23.06 Million). This is 102.63% lower than that of the Pharmaceuticals sector and 123.02% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.59% higher than that of the company.
Clearside EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearside Biomedical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearside Biomedical could also be used in its relative valuation, which is a method of valuing Clearside Biomedical by comparing valuation metrics of similar companies.Clearside Biomedical is currently under evaluation in ebitda category among its peers.
Clearside Biomedical Institutional Holders
Institutional Holdings refers to the ownership stake in Clearside Biomedical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Clearside Biomedical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Clearside Biomedical's value.| Shares | Northern Trust Corp | 2024-09-30 | 133.5 K | Rosalind Advisors, Inc. | 2024-09-30 | 127.2 K | Pnc Financial Services Group Inc | 2024-09-30 | 107.9 K | Brown Wealth Management, Llc | 2024-09-30 | 100 K | Northeast Financial Consultants, Inc | 2024-09-30 | 93 K | Captrust Financial Advisors | 2024-06-30 | 87 K | Johnson & Johnson | 2024-09-30 | 82.5 K | Citadel Advisors Llc | 2024-09-30 | 71.6 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 62.1 K | Vanguard Group Inc | 2024-09-30 | 2.8 M | Carmignac Gestion | 2024-06-30 | 2.1 M |
Clearside Fundamentals
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (84.33) % | ||||
| Current Valuation | 56.83 M | ||||
| Shares Outstanding | 75.84 M | ||||
| Shares Owned By Insiders | 7.38 % | ||||
| Shares Owned By Institutions | 23.16 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Earning | 130.00 X | ||||
| Price To Book | 3.93 X | ||||
| Price To Sales | 10.79 X | ||||
| Revenue | 8.23 M | ||||
| Gross Profit | 1.12 M | ||||
| EBITDA | (23.06 M) | ||||
| Net Income | (32.48 M) | ||||
| Cash And Equivalents | 29.03 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 43 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.56 X | ||||
| Book Value Per Share | (0.25) X | ||||
| Cash Flow From Operations | (18.14 M) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 30 | ||||
| Beta | 2.33 | ||||
| Market Capitalization | 81.15 M | ||||
| Total Asset | 34.02 M | ||||
| Retained Earnings | (320.92 M) | ||||
| Working Capital | 23.31 M | ||||
| Current Asset | 20.48 M | ||||
| Current Liabilities | 5.2 M | ||||
| Net Asset | 34.02 M |
About Clearside Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearside Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearside Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearside Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Clearside Biomedical Piotroski F Score and Clearside Biomedical Altman Z Score analysis. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.